COMP <GO>
NVAX vs LLY // DIVIDEND YIELD & FCF PAYOUT SAFETY
Novavax Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: NVAX 7
— LLY 6
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: LLY
LAST: $10.47 (+1.45%) • MKT CAP: $1.73B
dividend-safety
0.00%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
dividend-safety
0.49%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVAX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NVAX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 93.50% | 83.64% | +9.86 | NVAX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 32.36% | +52.64 | NVAX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.3x | 36.4x | -33.12 | NVAX | /valuation <GO> |
| Free Cash Flow Yield | -14.17% | 2.30% | -16.47 | LLY | /fcf-yield <GO> |
| Operating Margin | 40.30% | 40.21% | +0.09 | NVAX | /operating-margins <GO> |
| Net Profit Margin | 39.20% | 31.90% | +7.30 | NVAX | /net-margins <GO> |
| Revenue Growth (YoY) | 64.70% | 45.51% | +19.19 | NVAX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 9.29 | -9.09 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 66.6 | -18.30 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 3.5x | 30.6x | -27.12 | NVAX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.73B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NVAX REV | LLY REV | NVAX GROSS % | LLY GROSS % | NVAX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.12B | $65.18B | 93.5% | 83.0% | -$244.6M | $16.81B |
| FY 2024 | $682.2M | $45.04B | 70.3% | 81.3% | -$87.3M | $8.82B |
| FY 2023 | $983.7M | $34.12B | — | 79.3% | -$714.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVAX // BETA —
LLY // BETA 0.51